Results 91 to 100 of about 37,394 (238)

Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. [PDF]

, 2015
Cardiac involvement determines outcome in patients with systemic amyloidosis. There is major unmet need for quantification of cardiac amyloid burden, which is currently only met in part through semi-quantitative bone scintigraphy or Cardiovascular ...
Bandula, S, Fontana, M, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Herrey, AS, Moon, JC, Punwani, S, Taylor, SA, Treibel, TA, White, SK   +10 more
core   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Amyloidosis – short review

Journal of Medical Science, 2016
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type.
Agnieszka Danuta Gaczkowska, Paweł Jagodziński, Adrianna Mostowska   +2 more
doaj   +1 more source

Acute kidney injury on chronic kidney disease: From congestive heart failure to light chain deposition disease and cast nephropathy in multiple myeloma [PDF]

, 2019
Acute on chronic renal failure is a common but notably broad diagnosis. We present a 64-year-old man with a history of diastolic heart failure and chronic kidney disease, admitted for an elevated creatinine.
Cheng, Steven, Lacasse, Alexandre, Nwankwo, Christian, Shaikh, Sana   +3 more
core   +1 more source

Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy [PDF]

, 2015
Background: Hypertrophic cardiomyopathy (HCM) is a common cardiac disease caused by a range of genetic and acquired disorders. The most common cause is genetic variation in sarcomeric proteins genes.
Rosmini, Stefania <1981>
core   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source

Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis

Molecules, 2021
Inhibition of amyloid fibril formation could benefit patients with systemic amyloidosis. In this group of diseases, deposition of amyloid fibrils derived from normally soluble proteins leads to progressive tissue damage and organ failure.
Gareth J. Morgan
doaj   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown. Methods A retrospective analysis was conducted using the
Bilal Hussain, Sanchit Duhan, Khawaja Hassan Akhtar, Amith Reddy Seri, Krittapoom Akrawinthawong, Janardhana Gorthi, Bijeta Keisham, Tarun Dasari   +7 more
wiley   +1 more source

Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney [PDF]

Blood, 2008
Abstract Introduction: The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy have not been well described in this patient group Patients: 145 patients with AL who participated
Morie A, Gertz, Nelson, Leung, Martha Q, Lacy, Angela, Dispenzieri, Steven R, Zeldenrust, Suzanne R, Hayman, Francis K, Buadi, David, Dingli, Philip R, Greipp, Shaji K, Kumar, John A, Lust, S Vincent, Rajkumar, Stephen J, Russell, Thomas E, Witzig   +13 more
openaire   +2 more sources